成纤维细胞生长因子-23在系统性硬化症女性钙化症中的作用。

IF 1 4区医学 Q4 RHEUMATOLOGY

Acta reumatologica portuguesa Pub Date : 2020-10-01

Lucia Cantero-Nieto, Antonio Alvarez-Cienfuegos, Jose Alberto García-Gómez, Javier Martin, Miguel Angel González-Gay, Norberto Ortego-Centeno

{"title":"成纤维细胞生长因子-23在系统性硬化症女性钙化症中的作用。","authors":"Lucia Cantero-Nieto, Antonio Alvarez-Cienfuegos, Jose Alberto García-Gómez, Javier Martin, Miguel Angel González-Gay, Norberto Ortego-Centeno","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: Systemic sclerosis (SSc) is a complex disorder of unknown etiology. The purpose of this study was to evaluate fibroblast growth factor-23 (FGF-23) serum levels in women with SSc compared with healthy controls and to examine a possible association between FGF-23 serum levels with the presence of calcinosis in SSc patients.Methods: This cross-sectional study was performed in San Cecilio Hospital, Granada (Spain) from November 2017 to May 2019. Sixty-two women with SSc and 62 age and sex matched healthy controls were included in this study. FGF-23 serum concentration was evaluated by indirect enzyme-linked immunosorbent assay (ELISA).Results: There was no significant difference in FGF-23 levels between SSc patients and healthy controls (78.2 ± 60.5 vs. 80.3 ± 56.3 pg/mL, p= 0.662). Regarding the characteristics of the disease, we found a relationship between the values of FGF-23 and the presence of calcinosis. The levels of FGF-23 are higher in patients suffering from calcinosis (p= 0.028).Conclusion: We observed the presence of higher levels of serum FGF-23 in SSc female patients with calcinosis. Therefore, FGF-23 could be a possible therapeutic target for future treatments.","PeriodicalId":7229,"journal":{"name":"Acta reumatologica portuguesa","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Role of fibroblast growth factor-23 in calcinosis in women with systemic sclerosis.\",\"authors\":\"Lucia Cantero-Nieto, Antonio Alvarez-Cienfuegos, Jose Alberto García-Gómez, Javier Martin, Miguel Angel González-Gay, Norberto Ortego-Centeno\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Systemic sclerosis (SSc) is a complex disorder of unknown etiology. The purpose of this study was to evaluate fibroblast growth factor-23 (FGF-23) serum levels in women with SSc compared with healthy controls and to examine a possible association between FGF-23 serum levels with the presence of calcinosis in SSc patients.Methods: This cross-sectional study was performed in San Cecilio Hospital, Granada (Spain) from November 2017 to May 2019. Sixty-two women with SSc and 62 age and sex matched healthy controls were included in this study. FGF-23 serum concentration was evaluated by indirect enzyme-linked immunosorbent assay (ELISA).Results: There was no significant difference in FGF-23 levels between SSc patients and healthy controls (78.2 ± 60.5 vs. 80.3 ± 56.3 pg/mL, p= 0.662). Regarding the characteristics of the disease, we found a relationship between the values of FGF-23 and the presence of calcinosis. The levels of FGF-23 are higher in patients suffering from calcinosis (p= 0.028).Conclusion: We observed the presence of higher levels of serum FGF-23 in SSc female patients with calcinosis. Therefore, FGF-23 could be a possible therapeutic target for future treatments.\",\"PeriodicalId\":7229,\"journal\":{\"name\":\"Acta reumatologica portuguesa\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2020-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta reumatologica portuguesa\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta reumatologica portuguesa","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的:系统性硬化症(SSc)是一种病因不明的复杂疾病。本研究的目的是评估SSc女性与健康对照者的血清成纤维细胞生长因子-23 (FGF-23)水平，并研究SSc患者血清FGF-23水平与钙沉着症之间的可能关联。方法:本横断面研究于2017年11月至2019年5月在西班牙格拉纳达的圣塞西利奥医院进行。本研究包括62名SSc女性和62名年龄和性别匹配的健康对照。采用间接酶联免疫吸附试验(ELISA)评价血清FGF-23浓度。结果:SSc患者与健康对照组FGF-23水平差异无统计学意义(78.2±60.5 vs 80.3±56.3 pg/mL, p= 0.662)。关于该疾病的特征，我们发现FGF-23的值与钙沉着症的存在之间存在关系。钙质沉着症患者的FGF-23水平较高(p= 0.028)。结论:我们观察到伴有钙质沉着症的SSc女性患者血清FGF-23水平升高。因此，FGF-23可能成为未来治疗的潜在靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Role of fibroblast growth factor-23 in calcinosis in women with systemic sclerosis.

Objective: Systemic sclerosis (SSc) is a complex disorder of unknown etiology. The purpose of this study was to evaluate fibroblast growth factor-23 (FGF-23) serum levels in women with SSc compared with healthy controls and to examine a possible association between FGF-23 serum levels with the presence of calcinosis in SSc patients.

Methods: This cross-sectional study was performed in San Cecilio Hospital, Granada (Spain) from November 2017 to May 2019. Sixty-two women with SSc and 62 age and sex matched healthy controls were included in this study. FGF-23 serum concentration was evaluated by indirect enzyme-linked immunosorbent assay (ELISA).

Results: There was no significant difference in FGF-23 levels between SSc patients and healthy controls (78.2 ± 60.5 vs. 80.3 ± 56.3 pg/mL, p= 0.662). Regarding the characteristics of the disease, we found a relationship between the values of FGF-23 and the presence of calcinosis. The levels of FGF-23 are higher in patients suffering from calcinosis (p= 0.028).

Conclusion: We observed the presence of higher levels of serum FGF-23 in SSc female patients with calcinosis. Therefore, FGF-23 could be a possible therapeutic target for future treatments.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Acta reumatologica portuguesa 医学-风湿病学

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Acta Reumatólogica Portuguesa is a scientific peer reviewed journal covering all aspects of rheumatic diseases and related to Rheumatology. The journal publishes original articles, reviews, clinical cases, images in rheumatology, letters to the editor and clinical teaching (e.g. guidelines and clinical protocols). Published since 1973, Acta Reumatológica Portuguesa is the official scientific publication of the Portuguese Society of Rheumatology, a non-profit organization that promotes the knowledge and investigation of rheumatic diseases and the development of Rheumatology.